|
oka2008
Document Outline - WT1 peptide vaccine for the treatment of cancer
- Introduction
- Identification of WT1 protein-derived CTL epitopes and in vitro generation of WT1-specific CTLs
- Spontaneous immune responses against WT1 protein in cancer patients
- Mouse in vivo models for WT1 peptide cancer vaccine
- Clinical trials of WT1 peptide cancer vaccine
- Clinical responses
- Patients with myeloid malignancies, including AML and MDS
- Patients with multiple myeloma (MM)
- Patients with MDS, vaccinated with ‘very low dose’ of WT1 peptide
- Patients with solid cancer
- No damage to normal tissues by WT1 peptide vaccination
- Immunological responses and their correlation with clinical responses
- Perspectives
- New target diseases for WT1-directed cancer immunotherapy
- Enhancement of clinical efficacy and usefulness of WT1 peptide vaccine
- Translational research and reverse-translational research
- Evaluation of cancer vaccine-induced clinical responses
- Appropriate clinical settings for cancer vaccine
- Conclusion
- Acknowledgements
- References and recommended reading
Dostları ilə paylaş: |
|
|